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1. INTRODUCTION {#pedi12921-sec-0005}
===============

Diabetes mellitus is the most com*m*on metabolic disorder of childhood and its treatment requires patients to perform multiple actions throughout the day, including insulin dosing, blood glucose testing, and regular physical activity. Despite multiple advances in the treatment of type 1 diabetes mellitus (T1DM) (eg, use of blood glucose meters and insulin pumps, among others), more than 70% of T1DM patients maintain glycosylated hemoglobin (HbA~1C~) levels above 7%.[1](#pedi12921-bib-0001){ref-type="ref"} In addition, non‐compliance rates in patients with diabetes often exceed 50%, highlighting the need for interventions focused on behavior change.[2](#pedi12921-bib-0002){ref-type="ref"}

Studies of multidisciplinary interventions in T1DM have shown that they generate additional benefits compared to traditional diabetes education programs.[3](#pedi12921-bib-0003){ref-type="ref"} Some interventions in particular, such as psycho‐educational interventions, have been shown to be effective in improving glycemic control[4](#pedi12921-bib-0004){ref-type="ref"} and other outcomes in T1DM (diabetes stress, depressive symptoms, resilience, etc.).[5](#pedi12921-bib-0005){ref-type="ref"} Other interventions, such as the "Herdecker Kids with Diabetes" program, which is based on an anthropological and philosophical understanding of the human being, offer individualized, patient‐oriented approaches to developing comprehensive human and diabetes‐related skills.[6](#pedi12921-bib-0006){ref-type="ref"} However, despite the benefit of these multidisciplinary programs based on education and self‐management, life expectancy in these patients is still much lower than that observed in non‐diabetic persons.[7](#pedi12921-bib-0007){ref-type="ref"}

Self‐blood glucose monitoring (SBGM)[8](#pedi12921-bib-0008){ref-type="ref"}, [9](#pedi12921-bib-0009){ref-type="ref"} remains the predominant modality of glucose monitoring in diabetes compared to continuous glucose monitoring (CGM).[10](#pedi12921-bib-0010){ref-type="ref"} Although very useful, CGM is expensive, invasive, requires high management skills to be effective, and is difficult to implement in low‐income countries.[11](#pedi12921-bib-0011){ref-type="ref"} In the Diabetes Control and Complications Trial (DCCT), the time in range has been associated, using 7‐point monitoring, with lower risk of developing chronic complications in patients with T1DM. This strategy offers the possibility of improving success from any intervention, in situations where CGM is not feasible (eg, due to cost of CGM in developing countries).[8](#pedi12921-bib-0008){ref-type="ref"}, [9](#pedi12921-bib-0009){ref-type="ref"} Multidisciplinary interventions, particularly those based on SBGM, may therefore be effective in helping people with T1DM achieve their therapeutic goals in developing countries.

To date, in developing countries such as Mexico, there is no information available on the effect of multidisciplinary interventions that use glycemic self‐management as a fundamental tool on the management of children and adolescents with DM. The purpose of this study was therefore to evaluate an intervention (PAANDA: program of care for adolescents and children with diabetes mellitus) that includes multidisciplinary care at the first level of care. The 6‐month study focused on improving disease control through self‐management of blood glucose by SBGM at seven‐time points of the day, as well as HbA~1C~ levels.

2. METHODS {#pedi12921-sec-0006}
==========

2.1. Population {#pedi12921-sec-0007}
---------------

Patients admitted to the program were referred by local health centers, general hospitals, pediatric hospitals, National Institutes of Health, childhood obesity clinics, and private hospitals of any level of care. The patients included in this study were all those referred by local health centers. Inclusion criteria were age (0‐18 years, 11 months) and absence of acute complications at baseline. Patients were selected from January 2014 to September 2018. All patients had received some form of treatment at the time of inclusion. This program began as a private initiative in 2014 and is currently a primary care program for the very low‐income population of Mexico City, Mexico. This project was approved by the Institutional Review Board of the National Cancer Institute---Mexico (INCAN/CEI/699/19).

2.2. Registration of clinical characteristics {#pedi12921-sec-0008}
---------------------------------------------

Data were recorded in predefined formats and given to the patient during medical consultations; rigorous training was provided to the patient and the responsible family member. Trained staff then scanned each form into Excel spreadsheets to create standardized for analysis.

2.3. Intervention {#pedi12921-sec-0009}
-----------------

The PAANDA program includes the processes necessary to empower children and adolescents living with diabetes in a logical and systematic way. PAANDA consists of a series of multidisciplinary interventions---supported by up‐to‐date documentation---that form an individualized approach for child or adolescent with diabetes. This intervention, designed primarily as an educational model, has been formalized over time with the primary goal of allowing the patient to correct blood glucose levels through dietary measures or administration of additional insulin, trying to maintain glucose levels within the normal range, and thus prevent acute and chronic complications. Patients are encouraged to monitor glucose levels before and after breakfast, before and after lunch, before and after dinner, and in the early morning. The interdisciplinary care plan includes three integrative areas: social work, pediatric nursing and endocrinology; and several complementary services: ophthalmology, orthopedics, sports medicine, diabetes education, nutrition, psychology, podiatry, gastronomy, dentistry, and physical activity. Patients were treated with insulin and metformin, depending on the specific needs of each case. Although the study lasted 6 months, children were asked to continue with clinical and metabolic profiling after the 6‐month period, as part of their standard care follow‐up.

2.4. Statistical analysis {#pedi12921-sec-0010}
-------------------------

A descriptive analysis of the available clinical variables and the various multidisciplinary evaluations were carried out. Glucose levels and HbA~1C~ levels were determined during the first month of the intervention and compared to the measurement of the same variables obtained during the sixth month of the intervention. Statistically significant differences were also determined between the frequencies of patients in the American Diabetes Association categories (before meals: hypoglycemia, ADA 1, \<70 mg/dL; normal range, ADA 2, 70‐120 mg/dL; hyperglycemia, ADA 3, \>120 mg/dL; after meals: ADA 1, \<70 mg/dL; ADA 2, 70‐180 mg/dL; and ADA 3, \>180 mg/dL). Finally, using a multivariate‐adjusted logistic regression model, we determined the effect of time spent in the program on achieving adequate blood glucose levels (ADA 2). It was adjusted by age at the start of the program, type of diabetes (T1DM vs T2DM), sex, and diabetes duration at the start of the program. We included data on all patients, regardless of type of diabetes. *P*‐values \<.05 were considered statistically significant. The analyses were carried out using R software (R Project for Statistical Computing, CRAN, The Comprehensive R Archive Network, Vienna).

3. RESULTS {#pedi12921-sec-0011}
==========

3.1. Characteristics of the population studied and the intervention {#pedi12921-sec-0012}
-------------------------------------------------------------------

A total of 121 patients were included in the study, with a mean age of 14.27 years (SD 4.46 years); 59.50% were female. Mean diabetes duration at start of the program was 3.3 years (SD: 3.96 years). Patients had an average of 1.2 hospitalizations before entering the program. The majority was classified as T1DM (74.38%), the rest as T2DM, according to clinical criteria (ADA or ISPAD: International Society for Pediatric and Adolescent Diabetes). Details of population characteristics are shown in Table [1](#pedi12921-tbl-0001){ref-type="table"}. All patients received multidisciplinary care.

###### 

Socio‐demographic and clinical characteristics of patients seen within the first 6 months of the program of care for adolescents and children with diabetes mellitus (PAANDA, N = 121)

  Variable                                                          Mean    SD
  ----------------------------------------------------------------- ------- -------
  Age at time of entry                                              14.27   4.46
  Age at time of diagnosis, years                                   11.06   3.81
  Years elapsed from diagnosis to start of program                  3.33    3.96
  Number of hospitalizations                                        1.2     1.62
  Number of glucose tests[a](#pedi12921-note-0003){ref-type="fn"}   163.9   70.55

  Variable                    n    \%
  --------------------------- ---- -------
  Gender                           
  Women                       72   59.50
  Men                         49   40.50
  Type of diabetes mellitus        
  Type 1                      90   74.38
  Type 2                      31   25.62

  Interventions[b](#pedi12921-note-0004){ref-type="fn"}          
  ------------------------------------------------------- ------ ------
  Nutrition                                               3.11   2.73
  Educational Sessions                                    4.72   3.31
  Physical activity (sport)                               1.72   2.03
  Gastronomy                                              1.23   1.37
  Orthopedics                                             1.7    0.89
  Foot care                                               2.1    1.42
  Psychology                                              2.48   2.29
  Social work                                             1.64   1.36
  Ophthalmology                                           1.91   1.08
  Dentist                                                 2.08   2.43

Glucose tests per patient.

Some services (gastronomy, physical activation, social work and nursing) are not shown in the table.

Sessions per patient.

3.2. Effect of intervention on glycemic control {#pedi12921-sec-0013}
-----------------------------------------------

It was found that glucose levels, at all points of testing showed statistically significant differences in the sixth month, compared to the levels recorded in the first month (*P*‐value *\<*.001). Before breakfast, there was a reduction in the rates of hypoglycemia (−1.18%), as well as hyperglycemia (−19.50%), with a 20.67% increase in the frequency of levels in the normal ADA range. After breakfast, similarly, there were lower rates of hypoglycemia (−0.41%) and hyperglycemia (−7.73%) with an 8.14% increase in frequency normal values. The same trend was observed in almost all other time points, with similar intensities of change: ADA 1: mean, −0.55% (SD 1.72%); ADA 2: mean 10.55% (SD 5.03%); ADA 3: mean − 10% (SD 4.75%), which were statistically significant (*P*‐value \<.05, Table [2](#pedi12921-tbl-0002){ref-type="table"}).

###### 

Effect of the intervention on the percentage of patients with low, normal, or elevated glucose levels according to the American Diabetes Association (ADA) in patients in the program of care for adolescents and children with diabetes mellitus (PAANDA) at baseline (first month, n = 121) and 6 months after the intervention (n = 54)

                                        First month   Sixth month                 
  ------------------------------------- ------------- ------------- ----- ------- ------------
  Glucose levels before breakfast                                                 
  Hypoglycemia (ADA 1), \<70 mg/dL      29            5.21          44    4.03    **\<.001**
  Normoglycemia (ADA 2), 70‐120 mg/dL   171           30.70         561   51.37   
  Hyperglycemia (ADA 3), \>120 mg/dL    357           64.09         487   44.60   
  Glucose levels after breakfast                                                  
  ADA 1, \<70 mg/dL                     82            4.83          35    4.42    **\<.001**
  ADA 2, 70‐180 mg/dL                   1071          63.07         564   71.21   
  ADA 3, \>180 mg/dL                    545           32.10         193   24.37   
  Pre‐meal glucose levels                                                         
  ADA 1, \<70 mg/dL                     126           7.32          67    8.22    **.02**
  ADA 2, 70--120 mg/dL                  621           36.08         335   41.10   
  ADA 3, \>120 mg/dL                    974           56.60         413   50.67   
  Post‐meal glucose levels                                                        
  ADA 1,\<70 mg/dL                      133           8.15          55    7.05    **\<.001**
  ADA 2, 70--180 mg/dL                  1045          64.03         567   72.69   
  ADA 3, \>180 mg/dL                    454           27.82         158   20.26   
  Pre‐dinner glucose levels                                                       
  ADA 1, \<70 mg/dL                     62            3.75          43    5.40    **\<.001**
  ADA 2, 70--120 mg/dL                  554           33.54         359   45.04   
  ADA 3, \>120 mg/dL                    1036          62.71         395   49.56   
  After‐dinner glucose levels                                                     
  ADA 1, \<70 mg/dL                     95            6.65          21    2.96    **\<.001**
  ADA 2, 70--180 mg/dL                  918           64.29         540   76.16   
  ADA 3, \>120 mg/dL                    415           29.06         148   20.87   
  Early morning glucose levels                                                    
  ADA 1, \<70 mg/dL                     71            4.51          24    4.49    **.001**
  ADA 2, 70--180 mg/dL                  1067          67.70         405   75.70   
  ADA 3, \>180 mg/dL                    438           27.79         106   19.81   

Note: *P*‐values in bold: Statistically significant (*P* = 0.001), corresponds to the three categories.

Number of glycometrics by month in the total population evaluated.

3.3. Effect of intervention on HbA~1C~ levels {#pedi12921-sec-0014}
---------------------------------------------

Statistically significant reduction in HbA~1C~ levels was seen when all age groups were included: average reduction of 1.8% (*P*‐value = .018). This reduction was −1.5% in the \<8 years age group, −2.3% in the 8 to 13 years age group, and − 1.4% for the \>13 age group; however, the reductions by age group did not reach statistical significance (*P*‐values: .157 (\<8 years), 0.087 (8‐13 years), and .135 (\>13 years)(Table [3](#pedi12921-tbl-0003){ref-type="table"}), perhaps because of a reduction in statistical power due to smaller numbers in each category.

###### 

Effect of intervention on HbA~1C~ levels in adolescent and child care program with diabetes mellitus (PAANDA) patients at baseline and 4 to 6 months after intervention

                     First month   Fourth to sixth month                 
  ------------------ ------------- ----------------------- ------ ------ -----------
  All participants   10.01         2.47                    8.18   2.26   **0.018**
  \<8 years old      9.66          2.32                    8.18   2.26   0.157
  8‐13 years old     9.57          2.19                    7.32   2.60   0.087
  \>13 years old     10.21         2.58                    8.79   1.96   0.135

*Note*: *P‐values* in bold: Statistically significant.

3.4. Effect of time in the program on glycemic control {#pedi12921-sec-0015}
------------------------------------------------------

To determine, as a complementary outcome, the effect of the duration of intervention on glycemic control, a multivariate linear regression analysis was performed, including age at program entry, type of diabetes, gender, hospitalization, and diabetes duration as covariates. It was found that for each 30‐day treatment period, there was an average 13% increase in blood glucose levels in the normal range, which was statistically significant for all time points (Table [4](#pedi12921-tbl-0004){ref-type="table"}). In addition to the general downward trend in blood glucose levels, there was a decrease in measurement variability, both for pre‐meal (Figure [1](#pedi12921-fig-0001){ref-type="fig"}) and post‐meal (Figure [2](#pedi12921-fig-0002){ref-type="fig"}) quantifications. Notably, no increase in the frequency of hypoglycemia was observed. Finally, a Kernel diagram clearly showed a decrease in measurements above 200 mg/dL and an increase in peak measurements close to normal levels (Figure [3](#pedi12921-fig-0003){ref-type="fig"}).

###### 

Multivariable logistic regression model for the association between time in the program (every 30 days) and glycemic control in patients of the care program for adolescents and children with diabetes mellitus (PAANDA)

  Normal glucose     Univariable                    Multivariable                            
  ------------------ ------------- ---------------- --------------- ------- ---------------- ------------
  Before breakfast   1.131         (1.094, 1.162)   **\<.001**      1.136   (1.094, 1.162)   **\<.001**
  After breakfast    1.125         (1.094, 1.162)   **\<.001**      1.131   (1.094, 1.162)   **\<.001**
  Before lunch       1.099         (1.062, 1.127)   **\<.001**      1.117   (1.094, 1.162)   **\<.001**
  After lunch        1.159         (1.127, 1.197)   **\<.001**      1.172   (1.127, 1.197)   **\<.001**
  Before dinner      1.127         (1.094, 1.162)   **\<.001**      1.144   (1.127, 1.161)   **\<.001**
  After dinner       1.157         (1.127, 1.197)   **\<.001**      1.160   (1.127, 1.197)   **\<.001**

*Note*: Adjusted by age at start of program, type of diabetes, gender, hospitalization, and time with illness. Before meals: 70‐120 mg/dL; after meals: 70‐180 mg/dL.

Abbreviations: ADA, American Diabetes Association; HR, hazards ratio; 95% CI, 95% confidence Interval.

![Conditional mean smoothed for the effect of time in the program on glucose levels before: A, breakfast, B, lunch, and C, dinner, in children and adolescents with diabetes mellitus treated within the PAANDA (Care Program for Adolescents and Children with Diabetes Mellitus) program](PEDI-21-61-g001){#pedi12921-fig-0001}

![Conditional mean smoothed for the effect of time in the program on glucose levels, after: A, breakfast, B, lunch, and C, dinner, in children and adolescents with diabetes mellitus treated within the Care Program for Adolescents and Children with Diabetes Mellitus (PAANDA) program](PEDI-21-61-g002){#pedi12921-fig-0002}

![Kernel curve for the effect of the Care Program for Adolescents and Children with Diabetes Mellitus (PAANDA) program in children and adolescents with diabetes mellitus on glucose levels. A, first month of treatment, B, sixth month of treatment, and C, first and sixth month combined](PEDI-21-61-g003){#pedi12921-fig-0003}

4. DISCUSSION {#pedi12921-sec-0016}
=============

This study showed that an interdisciplinary intervention that included medical, psychological, nutritional, social, diabetes education, and other interventions improve not only glycemic levels, but also glycemic variability, and HbA~1C~ levels within 6 months. Despite advances in insulin preparations, insulin delivery devices, and new blood glucose monitoring technologies, glycemic control in most patients with T1DM remains sub‐optimal. In this context, multidisciplinary interventions represent a good opportunity to improve glycemic control, especially where new technologies are not available for any reason---high costs, logistics, etc. One of the authors of this program (F.R.) has suggested that they be included in more recent national recommendations for the treatment of DM in young people.[12](#pedi12921-bib-0012){ref-type="ref"} Although empowering patients through multidisciplinary interventions will allow them to optimize resources to improve diabetes control, and avoid acute and chronic complications, appreciation of the costs of the multidisciplinary interventions themselves, for example, the cost of training and making available the manpower involved, in relation to new technologies, which requires further research.

It is important to reduce glycemic variability because it is well known that it is an important predictor of hypoglycemia[13](#pedi12921-bib-0013){ref-type="ref"}, [14](#pedi12921-bib-0014){ref-type="ref"} and correlates with poor glycemic control.[14](#pedi12921-bib-0014){ref-type="ref"} Glycemic variability has a strong association with the thickening of the carotid intima‐media, with the risk of micro‐vascular complications,[15](#pedi12921-bib-0015){ref-type="ref"} and is an independent predictor of patient satisfaction with an intensive insulin regimen, independent of other glycemic control measures.[16](#pedi12921-bib-0016){ref-type="ref"} In addition to the decrease in blood glucose levels, it was clearly observed in this study that there was also a significant decrease in its variability over the period evaluated. This suggests that patients in the PAANDA program may benefit from additional changes that contribute to better long‐term management.

Data from the *T1D Exchange Clinical Registry* (T1D Ex), which maintains records of 26 000 T1DM patients in the United States, indicate that the average HbA~1C~ in patients under 25 years of age ranges from 8.3% to 8.7%.[17](#pedi12921-bib-0017){ref-type="ref"} This study showed an average of 8.18% during the sixth month, with the intervention of the PAANDA program having significantly reduced HbA~1C~ by an average of 2.6%. The improved blood glucose monitoring and lower HbA~1C~ show better glycemic control after the intervention, even though the mean HbA~1C~ of 8.18% is higher than the recommended levels (\<7%).

The T1D Ex has identified that, in patients with T1DM, the use of CGM and frequent SBGM, as well as the use of insulin pumps, white race, family income, higher patient or parental education, and private insurance, are factors associated with better glycemic control.[17](#pedi12921-bib-0017){ref-type="ref"} The population assessed in this study tends to be homogeneous from the socio‐demographic point of view. However, there were internal factors, such as shortage of insulin supplies, whose impact on glycemic control in these patients should be examined, and which will be evaluated in future studies. In this study, we did not calculate any changes in insulin requirements, either in terms of their effect on clinical outcomes or the cost of treatment; these aspects will be published in subsequent analyses.

SBGM, which began with the introduction of glucose meters during the 1980s, had a major effect on the control of T1DM. Multiple studies have shown a good correlation between the frequency of self‐monitoring and glycemic control.[18](#pedi12921-bib-0018){ref-type="ref"} In this study, the main tool for glycemic control tool was self‐monitoring, which showed a significant improvement in almost all parameters evaluated. It is striking to note that the number of blood glucose tests performed is more than the number of suggested tests in countries with higher income levels (four times a day in Sweden).[19](#pedi12921-bib-0019){ref-type="ref"} PAANDA, with its strong educational component, could contribute to better control, by improving HbA~1C~ and time in range, by optimizing resources such as limited test strips. However, the ability to do self‐monitoring is limited by the availability of test strips, their cost, and, the lack of coverage by some insurers.[20](#pedi12921-bib-0020){ref-type="ref"} Further studies are needed to determine the relevance of these factors within this type of multidisciplinary programs.

We also observed significant changes in the number of absolute blood glucose measurements after the sixth month of intervention, for example, the absolute number of glucose measurements before breakfast increased from 557 at baseline to 1092 at 6 months, although in other time slabs, it decreased substantially. These changes in the number of glucose measurements may reflect lower compliance status in our patients, due to families\' economic constraints, in spite of the medical advice given in the program. The influence of socio‐economic factors will be assessed in future studies with this group of patients.

This study presents notable limitations. For example, there was a significant loss during follow‐up, which could suggest a potential bias in the conclusions. The study evaluates a program implemented for the first level of public attention that collected real‐world data. Differences in the number of measurements and the number of patients at the beginning and end are also evident. The study showed more patient measurements in the first month. In addition, the cross‐sectional analysis considered only those patients who reached the sixth month of the intervention, while many were at that time in month two, three, four, and five. Another key parameter to confirm better control is the presence of hypoglycemic or ketoacidosis events. Because of the before vs after design, our study was unable to determine whether the intervention improved these outcomes, although all the parameters suggest a metabolic improvement.

Other limitations of the study are: (a) Patients usually lack sufficient economic resources, which prevent the availability of adequate test strips for regular testing (ie, families had to pay for the test strips out of their pocket). Other patient factors which interfere with regular monitoring include denial of the disease and refusal of the patient to be monitored; (b) Diagnostic inputs: the availability of laboratory inputs is variable, which affects the frequency of HbA~1C~ measurements; (c) Commercial aspects: patients use multi‐brand meters, which they choose and pay for themselves, so the variability of the results obtained increases. However, despite all the above limitations, this is one of the first studies to collect and analyze data under real‐world conditions, based on which clinical decisions can be made, and which go beyond the perspective of a clinical trial, where many of the factors described are controlled. These factors, particularly poverty, lack of availability of adequate test strips, denial of the disease, and refusal of the patient to be monitored, etc. have to be tackled by all health care teams to varying degrees. The potential influence of those factors needs further research.

Most children and adolescents with DM have suboptimal glycemic control. This can be attributed to the demanding nature of the disease, the presence of long‐term complications, self‐care capacity and associated costs, but there are also factors that can be improved, such as knowledge of the disease, physical activity, diet, and self‐care. The present study has shown that multidisciplinary intervention involving medical, nutritional, social, educational, and other interventions can improve glycemic levels, glycemic variability, and HbA~1C~ levels. Finally, it is necessary to mention that further studies are needed on the effect of interventions such as PAANDA on other equally relevant areas such as quality of life and the cost‐benefit ratios.
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